Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.
McDermott MS, Browne BC, Conlon NT, O'Brien NA, Slamon DJ, Henry M, Meleady P, Clynes M, Dowling P, Crown J, O'Donovan N. McDermott MS, et al. Among authors: conlon nt. Mol Cancer. 2014 Jun 24;13:157. doi: 10.1186/1476-4598-13-157. Mol Cancer. 2014. PMID: 24958351 Free PMC article.
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, Gallagher WM, Zagozdzon R, Watson WR, O'Donovan N, Crown J. Eustace AJ, et al. Among authors: conlon nt. BMC Cancer. 2018 Oct 11;18(1):965. doi: 10.1186/s12885-018-4852-1. BMC Cancer. 2018. PMID: 30305055 Free PMC article.
Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer.
Canonici A, Browne AL, Ibrahim MFK, Fanning KP, Roche S, Conlon NT, O'Neill F, Meiller J, Cremona M, Morgan C, Hennessy BT, Eustace AJ, Solca F, O'Donovan N, Crown J. Canonici A, et al. Among authors: conlon nt. Ther Adv Med Oncol. 2020 Jan 28;12:1758835919897546. doi: 10.1177/1758835919897546. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32064003 Free PMC article.
Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer.
Roche S, Gaule P, Winrow D, Mukherjee N, O'Neill F, Conlon NT, Meiller J, Collins DM, Canonici A, Fawsi MI, Estepa-Fernández A, Madden SF, Crown J, O'Donovan N, Eustace AJ. Roche S, et al. Among authors: conlon nt. PLoS One. 2023 Mar 15;18(3):e0282512. doi: 10.1371/journal.pone.0282512. eCollection 2023. PLoS One. 2023. PMID: 36920947 Free PMC article.
171 results